Compounds for the treatment of mycobacterial infections
The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
1. A compound of Formula Ia or a pharmaceutically acceptable salt thereof:
wherein:
R 1 is selected from the group consisting of phenyl, substituted phenyl, pyridinyl, and substituted pyridinyl;
R 3 is hydrogen or unsubstituted C 1 -C 8 alkyl;
R 4 is hydrogen or unsubstituted C 1 -C 8 alkyl;
R 2 is:
each R 6 , R 7 , R 10 and R 11 is independently selected from the group consisting of hydrogen and unsubstituted C 1 -C 8 alkyl;
R 5 is selected from the group consisting of:
R 100 is hydrogen or unsubstituted C 1 -C 8 alkyl; and
R 100 ′ is hydrogen or unsubstituted C 1 -C 8 alkyl;
wherein the substituted phenyl and the substituted pyridinyl are each independently substituted with one or more substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl,-alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,-alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxy, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, and sulfonyl.
2. The compound of claim 1 selected from the group consisting of:
4-(3 -aminophenyl)-5,7-dimethyl-6-(4-(morpholinomethyl)phenyl)-2H-chromen-2-one; and
4-phenyl-5,7-dimethyl-6-(4-(morpholinomethyl)phenyl)-2H-chromen-2-one, or a pharmaceutically acceptable salt of any of thereof.
3. The compound of claim 1 , wherein R 5 is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein R 3 is unsubstituted C 1 -C 8 alkyl, and R 4 is unsubstituted C 1 -C 8 alkyl, or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein R 1 is phenyl or substituted phenyl, or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
7. A compound selected from the table below, or a pharmaceutically acceptable salt thereof:
TABLE A
No
Structure
1
2
3
5
6
7
8
9
10
11
12
13
43
44
8. The compound of claim 1 , wherein R 5 is:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 , wherein R 5 is:
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 , wherein R 5 is:
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1 , wherein R 5 is:
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 8 , wherein R 100 is hydrogen, or a pharmaceutically acceptable salt thereof.
13. The compound of claim 9 , wherein R 100 is hydrogen, or a pharmaceutically acceptable salt thereof.
14. The compound of claim 10 , wherein R 100 is hydrogen, or a pharmaceutically acceptable salt thereof.
15. The compound of claim 11 , wherein R 100 is hydrogen, or a pharmaceutically acceptable salt thereof.
16. The compound of claim 15 , wherein R 100 ′ is hydrogen or methyl, or a pharmaceutically acceptable salt thereof.
17. The compound of claim 4 , wherein R 3 is unsubstituted C 1 -C 3 alkyl, and R 4 is unsubstituted C 1 -C 3 alkyl, or a pharmaceutically acceptable salt thereof.
18. The compound of claim 17 , wherein R 3 is methyl and R 4 is methyl, or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 7 , or a pharmaceutically acceptable salt thereof.